GMP validation – Page 11

Stage 2 PPQ Protocol Design for High-Risk Pharmaceutical Processes

Designing Stage 2 PPQ Protocols for High-Risk Pharmaceutical Processes Pharmaceutical manufacturing and quality assurance professionals face unique challenges when it comes to designing Stage 2 Protocols for Process Performance Qualification…

Stage 2 PPQ Protocol Design for High-Risk Pharmaceutical Processes

Designing Stage 2 PPQ Protocol for High-Risk Pharmaceutical Manufacturing In advanced pharmaceutical manufacturing, particularly for high-risk processes, establishing an effective Stage 2 Process Performance Qualification (PPQ) protocol is crucial. Regulatory…

Common Stage 1 Process Validation Gaps Found During Regulatory Inspections

Addressing Common Gaps in Stage 1 Process Validation During Inspections Pharmaceutical manufacturing is a complex process that must be governed by strict regulatory frameworks to ensure safety and efficacy. One…

How to Build a Stage 1 Process Design Package That Supports PPQ

Creating an Effective Stage 1 Process Design Package for PPQ Support The successful execution of pharmaceutical process validation is pivotal in ensuring product quality and compliance with regulatory expectations. Especially…

Process Validation Stage 1–3 Explained for GMP Manufacturing Teams

Understanding Phase 1 Through 3 of Process Validation for GMP Teams In the realm of pharmaceutical manufacturing, understanding the intricacies of process validation is a foundational element for ensuring product…

How to Defend Worst-Case Product Selection During FDA and EU GMP Inspections

Defending Against Challenges in Worst-Case Product Selection During GMP Inspections In the realm of pharmaceutical manufacturing and quality control, maintaining compliance during inspections is paramount. A crucial aspect of this…

Worst-Case Product Selection and Residue Carryover Risk in Shared Facilities

Addressing Residue Carryover Risks in Shared Facilities: Effective Worst-Case Product Selection Strategies In the pharmaceutical manufacturing sector, the risk of residue carryover is a critical concern, particularly in shared facilities.…

Worst-Case Product Selection for Products with Insoluble Colorants or Coatings

Addressing Challenges in Worst-Case Product Selection with Insoluble Colorants or Coatings The integration of insoluble colorants or coatings in pharmaceutical products poses significant challenges during manufacturing, particularly related to cleaning,…

Worst-Case Product Selection for Products with Similar APIs but Different Excipients

Addressing Challenges in Worst-Case Product Selection for Products with Similar APIs but Varying Excipients In pharmaceutical manufacturing, selecting the appropriate worst-case product for cleaning validation and cross-contamination risk assessments can…

Worst-Case Product Selection for Campaign Manufacturing and Extended Runs

Navigating Worst-Case Product Selection for Campaign Manufacturing Risks In the pharmaceutical manufacturing landscape, especially when dealing with campaign production and extended runs, choosing the appropriate products becomes critical. A miscalculation…

Worst-Case Product Selection for Campaign Manufacturing and Extended Runs

Addressing Challenges in Worst-Case Product Selection for Manufacturing Campaigns Pharmaceutical manufacturing often involves complex product portfolios, requiring careful selection procedures, especially during campaigns that demand shared equipment. The failure to…

Worst-Case Product Selection for CIP Cleaning Processes

Strategies for Addressing Worst-Case Product Selection in CIP Cleaning Processes In the realm of pharmaceutical manufacturing, effective cleaning processes are critical for maintaining product integrity and ensuring compliance with regulatory…